Viral Vector Production - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others), By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish), By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research), By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), By Region, Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 5.22 billion

CAGR (2023-2028)

14.21%

Fastest Growing Segment

Adeno-Associated Virus Vectors

Largest Market

North America

 

Market Overview

Global Viral Vector Production Market has valued at USD 5.22 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 14.21% through 2028. Viral vector production refers to the process of creating and manufacturing modified viruses, known as viral vectors, that are used to deliver genetic material into target cells for various purposes, primarily in medical and biotechnological applications. Viral vectors are a critical tool in gene therapy, gene editing, and other advanced therapeutic approaches. They are designed to be safe and efficient carriers for delivering therapeutic genes, correcting genetic mutations, or manipulating cellular processes.

Different types of viruses can be used as vectors, including adeno-associated viruses (AAV), lentiviruses, adenoviruses, and others. The choice of viral vector type depends on factors such as the target cells, the therapeutic gene to be delivered, and the desired duration of gene expression. The viral vector's genetic material is modified to remove or replace its disease-causing components and to include the therapeutic gene of interest. The increasing success and approval of gene therapies for various diseases, such as genetic disorders and certain types of cancer, have driven the demand for viral vectors as essential delivery tools for therapeutic genes.

The prevalence of genetic disorders and diseases that have a genetic component has led to a growing need for targeted and effective therapies. Viral vectors offer a means to deliver corrective or therapeutic genes to affected cells, making them a vital component in treating such conditions. Biotechnology companies, pharmaceutical firms, academic institutions, and research organizations are investing heavily in the research and development of gene therapies. This increased investment in the field directly drives the demand for viral vectors and their production.

 Key Market Drivers

Pioneering Clinical Success of Viral Vector Production

Pioneering clinical successes of viral vector production are instances where viral vectors have been used effectively in medical treatments and therapies, resulting in positive outcomes for patients. These successes demonstrate the potential of viral vector-based approaches to address a variety of diseases and conditions. Luxturna, developed by Spark Therapeutics, was one of the first gene therapies approved by the U.S. FDA for the treatment of an inherited retinal disease called Leber congenital amaurosis (LCA). It uses adeno-associated virus (AAV) vectors to deliver a functional copy of the RPE65 gene to retinal cells, restoring vision in patients with a specific genetic mutation. Zolgensma, developed by AveXis (now a part of Novartis), is a gene therapy for the treatment of spinal muscular atrophy (SMA), a severe neuromuscular disorder.

It utilizes an AAV9 vector to deliver a functional copy of the SMN1 gene, which is deficient in SMA patients. Zolgensma has shown remarkable success in improving motor function and survival in infants with SMA. Researchers have achieved promising results in treating hemophilia B, a bleeding disorder caused by a deficiency of clotting factor IX. Viral vectors, often AAV, are used to deliver the functional factor IX gene to liver cells, enabling sustained production of the missing clotting factor. Early clinical trials have shown significant reductions in bleeding events. While not traditional viral vectors, CAR (chimeric antigen receptor) T-cell therapies use modified patient T cells to target and destroy cancer cells. Lentiviral vectors are often employed to introduce the CAR genes into T cells, making them cancer specific. CAR T-cell therapies have shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma. Lentiviral vectors, known for their ability to integrate into the host cell's genome, have been used in various clinical trials targeting diseases like beta-thalassemia, sickle cell disease, and HIV.

These therapies aim to correct genetic mutations or modify cells to confer resistance to diseases. Another type of gene therapy using AAV vectors, developed by Editas Medicine, aims to treat LCA10 caused by mutations in the CEP290 gene. The therapy aims to edit the gene using CRISPR-Cas9 technology delivered by AAV vectors to restore normal vision. These pioneering clinical successes highlight the transformative potential of viral vector-based therapies in treating a range of genetic and acquired diseases. They provide evidence of the feasibility of using viral vectors to deliver therapeutic genes or manipulate cellular processes effectively. This factor will accelerate the demand of Global Viral Vector Production Market.

Advancements in Vector Engineering

Advancements in vector engineering have played a crucial role in improving the efficiency, safety, and specificity of viral vectors used in various applications, including gene therapy, vaccine development, and gene editing. Vector engineering involves modifying the genetic makeup of viral vectors to enhance their performance, target specific cell types, and reduce potential side effects. Researchers have developed strategies to modify the viral vectors to exhibit improved tissue targeting. By engineering the viral surface proteins, such as capsid proteins in adenoviruses and adeno-associated viruses (AAV), vectors can be designed to interact more specifically with receptors on target cells, increasing transduction efficiency and reducing off-target effects. One of the challenges in viral vector-based therapies is the potential for the immune system to recognize and attack the vectors, limiting their efficacy. Vector engineering techniques aim to reduce immune responses by modifying vector components that trigger immune reactions.

For example, removing immunogenic regions from the vector's genome or capsid can help evade immune recognition. Researchers have engineered viral vectors to improve their ability to enter target cells and deliver their cargo. This can involve modifying viral surface proteins to enhance receptor binding and cellular uptake, leading to more efficient gene delivery. The therapeutic gene carried by the viral vector needs to be expressed at the appropriate levels and in the correct cell types. Advances in vector engineering include optimizing the promoters (regulatory sequences) that control gene expression to achieve desired levels of expression while minimizing off-target effects. Lentiviral vectors have the capacity to integrate their genetic material into the host cell's genome, which can lead to unpredictable effects. Researchers are developing methods to control the integration site, aiming for safer and more predictable outcomes by targeting specific genomic regions or using non-integrating vectors.

Alongside naturally occurring viral vectors, researchers are exploring synthetic vectors, which are designed from scratch rather than being derived from viruses. These synthetic vectors can be tailored for specific applications, allowing precise control over vector characteristics, such as size, stability, and immunogenicity. Advances in genome editing technologies like CRISPR-Cas9 have been integrated into viral vector platforms, allowing for simultaneous delivery of gene-editing tools and the therapeutic gene. This approach enables more targeted and precise genetic modifications. Some approaches involve engineering vectors with the ability to deliver multiple therapeutic genes simultaneously. This can be particularly useful for complex diseases where multiple genes need to be modulated. With the advancement of personalized medicine, there is a growing interest in engineering viral vectors tailored to individual patient needs. This can involve adapting vectors to specific genetic mutations or patient characteristics. This factor will pace up the demand of Global Viral Vector Production Market.

Growing Bioreactor Technology in Viral Vector Production

Bioreactor technology plays a vital role in the production of viral vectors for various applications, particularly in gene therapy, vaccine development, and gene editing. Bioreactors provide a controlled environment for the growth and propagation of cells that are used to produce viral vectors. This technology ensures consistent production of high-quality viral vectors on a scale that is necessary for clinical and commercial applications. Bioreactors are used to culture the cells that serve as hosts for producing viral vectors. Depending on the type of viral vector and cell line, different bioreactor configurations are employed, such as stirred-tank bioreactors or perfusion bioreactors. Bioreactors provide precise control over parameters like temperature, pH, dissolved oxygen levels, and nutrient supply. These conditions are optimized to support cell growth and vector production. In the case of viral vector production, cells are often transfected or infected with the recombinant viral vector to initiate the vector replication process.

Bioreactors facilitate efficient transfection or infection by ensuring proper mixing and distribution of the vector. Bioreactor technology allows us to produce viral vectors at larger scales, which is crucial when transitioning from research and development to clinical trials and commercial manufacturing. Bioreactors enable scalability while maintaining consistent quality. Bioreactors are equipped with sensors and monitoring systems that track various parameters in real-time, such as cell viability, growth rate, and metabolic activity. This data helps operators ensure optimal conditions and adjust the process as needed. After the cells have produced the viral vectors, the culture is harvested. Bioreactor systems may also include integrated technologies for initial purification steps, which can streamline downstream processing. By maintaining ideal growth conditions, bioreactor technology helps achieve higher viral vector yields while maintaining consistent quality and safety profiles.

The controlled and reproducible environment of bioreactors reduces variability in production compared to traditional methods, leading to more consistent product characteristics. In recent years, single-use bioreactors (SUBs) have gained popularity in viral vector production. SUBs offer advantages in terms of ease of use, reduced contamination risk, and faster turnaround times between batches. Bioreactor systems often come with software that facilitates process development and optimization. These tools enable researchers and operators to fine-tune production parameters efficiently. Bioreactors can be adapted to produce various types of viral vectors, including adenoviruses, lentiviruses, adeno-associated viruses (AAV), and more. This factor will help in the development of Global Viral Vector Production Market.


Download Free Sample Report

Key Market Challenges

Scalability and Commercialization

Scalability and commercialization are indeed significant challenges in viral vector production. While viral vectors have shown promise in preclinical and early clinical trials, transitioning from small-scale laboratory production to large-scale manufacturing for commercialization presents several complex hurdles. The production of viral vectors involves multiple steps, including cell culture, transfection or infection, purification, and quality control. Scaling up each of these steps while maintaining consistent product quality is intricate and requires careful optimization. Achieving high viral vector yields is essential for commercialization to meet the demands of larger patient populations. However, maintaining high productivity at large scales can be challenging due to factors such as oxygen transfer limitations, shear stress, and nutrient limitations. Adapting cell lines to large-scale production conditions can be time-consuming and may require substantial modifications to achieve desired yields. Ensuring stable and high-yielding cell lines is crucial for consistent production. As the production scale increases, ensuring the integrity and efficacy of the viral vectors becomes more complex. Factors such as vector aggregation, degradation, and loss of transduction efficiency need to be closely monitored and controlled. Designing and building manufacturing facilities capable of producing viral vectors at commercial scales require significant investments. These facilities must adhere to stringent quality and regulatory standards. The challenges associated with scalability and process development can lead to extended timelines for commercialization, delaying patient access to therapies.

Cost of Goods and Pricings

The cost of goods and pricing is a significant challenge in viral vector production for various applications, particularly in the context of gene therapy and advanced biotechnological treatments. The production of viral vectors often requires specialized bioreactors, purification systems, and analytical instruments. Designing and building facilities with these capabilities requires significant investment. Meeting stringent quality and regulatory standards is essential for the safety and efficacy of viral vector therapies. This requires robust quality control measures, extensive testing, and compliance with regulatory guidelines, all of which can contribute to higher costs. Culture media, growth factors, viral vector components, and other raw materials used in production can be expensive. Ensuring a reliable supply chain for high-quality materials is crucial but can add to the overall cost. The specialized nature of viral vector production requires skilled professionals with expertise in bioprocessing, cell culture, molecular biology, and regulatory compliance. Recruiting and retaining these experts can contribute to higher labor costs. While viral vectors hold great promise for addressing genetic and acquired diseases, their complex production processes, specialized requirements, and regulatory considerations can contribute to high production costs, which in turn can impact the affordability and accessibility of these therapies.

Key Market Trends

Manufacturing Process Optimization

As the field of gene therapy and biotechnology continues to advance, there is a growing emphasis on refining and improving the processes used to produce viral vectors. Optimizing the manufacturing process is essential to enhance efficiency, reduce costs, increase yields, and ensure the consistent quality and safety of viral vector-based therapies. Optimization efforts aim to increase the yield of viral vectors from each production run. This involves refining cell culture conditions, optimizing transfection or infection protocols, and enhancing vector production efficiency. Optimized processes are more robust and less susceptible to variations caused by changes in environmental conditions or raw materials. This reliability is crucial for maintaining consistent product quality. It also includes enhancing quality control measures to ensure the reproducibility and consistency of product attributes, meeting regulatory requirements and safety standards. Establishing standardized processes across different production sites or facilities ensures uniformity and reduces variability, facilitating technology transfer and regulatory approvals. Process optimization can lead to reduced resource consumption, waste generation, and energy usage, contributing to a more sustainable production process.

Segmental Insights

Vector Type Insights

In 2022, the Viral Vector Production market was dominated by the AAV segment and is predicted to continue expanding over the coming years. One of the main reasons for the segment’s expansion is the increasing need for AVV within the gene therapy industry. The Adeno virus associated vector (AVAV) was the main vector used in the clinical trials for gene therapy. Hence, the high demand in the market supports the growth of the segment.

Workflow Insights

In 2022, the Viral Vector Production market was dominated by downstream processing segment and is predicted to continue expanding over the coming years. The processing and delivery of viral vectors in the research environment is of paramount importance to ensure the quality and yield of the product. This has necessitated the optimization of downstream processing and upstream processing in order to meet the increasing demand for vectors in the production of gene and cell therapies. Companies are considering cutting-edge platforms to address the bottleneck in the manufacturing process.

Application Insights

In 2022, the Viral Vector Production market was dominated by gene therapy segment and is predicted to continue expanding over the coming years. Most of the revenue generated by the gene therapy segment is attributed to the high level of demand and capital expenditure for the development and commercialisation of gene therapies. Additionally, the potential to offer durable or long-term solutions for genetic diseases, cancers, and other conditions utilizing viral vectors has contributed to the growth of the segment.

End User Insights

In 2022, the Viral Vector Production market was dominated by research institutes segment and is predicted to continue expanding over the coming years. This is largely due to the global research community's strong commitment to developing cutting-edge therapies to treat a variety of inherited and acquired conditions that previously lacked a viable treatment.  approach.


Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Viral Vector Production Market. North America is well-positioned to reap the benefits of robust government support and financing for gene therapy and cutting-edge therapeutics research and development, allowing the region to remain at the cutting edge of innovation and accelerate the commercialization of viral vector-based therapies.

Recent Developments

  • In February 2023, Lonza Bioconjugation announced the successful completion of an expansion of its Bioconjugation Facility in Visp (CH) to support the growth of preclinical, clinical, and commercial bioconjugate products.
  • In January 2023, The Jointly Operated Viral Vector Contract Development and Manufacturing Organization (CDMO) of Charles River Laboratories International Inc. (CRI) has entered into a Strategic Partnership Agreement with the Joint-Operated Biosciences Corporation of South Korea (RBSC), a Biopharmaceutical Company specializing in RNA-based Gene Therapeutics.
  • In June 2022, Coave Therapeutics, and ABL, formed a strategic collaboration to develop gene therapy manufacturing methods and generate collaborative capabilities for AAV-based gene therapy process development.
  • In October 2022, Cytiva, a biopharmaceutical company specializing in the development of high-quality cell lines and the development of viral vector manufacturing technologies, has acquired CEVEC Pharma, a leading German company in the biomanufacturing industry, to further strengthen its position as a leader in the field.
  • In October 2022, ABL organization has formed a strategic partnership with RD-Biotech in GMP cell and gene therapy manufacturing to provide streamlined access for cell and gene therapy development for plasmid DNA manufacturing and viral vector manufacturing.
  • In December 2022, Merck and Synplogen have agreed to work together to speed up the development, manufacturing, and testing of viral vector gene treatments in Japan. The Memorandum of Understanding (MoU) is non-binding, but the two companies plan to pool their resources.
  • In January 2021, Thermo Fisher Scientific, a subsidiary of Thermo Fisher Scientific, Inc., has acquired Novasep S.A., a Belgian-based virus vector manufacturing business owned and operated through a manufacturing business, for an approximate sum of EUR 725 million, in cash. The business offers contract manufacturing services to produce vaccines and therapies for biotechnology companies and their biopharma customers.

Key Market Players

  • Merck kgaa
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A
  • Cobra Biologics Ltd.
  • Thermofisher Scientific Inc.
  • Waisman Biomanufacturing
  • Genezen Laboratories
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL inc.)
  • Novasep Holding s.a.s.
  • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
  • Takara Bio Inc.
  • RegenxBio, Inc.
  • Aldevron LLc.
  • Bluebird Bio Inc.

 

 By Vector Type

By Workflow

By Application

  By End-Use Industry

By Region

By Region
  • Adenovirus
  • AAV
  • Lentivirus
  • Retrovirus
  • Others
  • Upstream Processing
  • Vector amplification and expansion
  • Vector recovery/harvesting
  • Downstream Processing
  • Purification
  • Fill finish

 
  • Gene and Cell Therapy Development
  • Vaccine Development
  • Biopharmaceutical and Pharmaceutical Discovery
  • Biomedical Research

 
  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Others
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • South America
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East
Report Scope:

In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Viral Vector Production Market, By Vector Type:

o   Adenovirus

o   AAV

o   Lentivirus

o   Retrovirus

o   Others

  • Viral Vector Production Market, By Workflow:

o   Upstream Processing

o   Vector amplification and expansion

o   Vector recovery/harvesting

o   Downstream Processing

o   Purification

o   Fill finish

  • Viral Vector Production Market, By Application:

o   Gene and Cell Therapy Development

o   Vaccine Development

o   Biopharmaceutical and Pharmaceutical Discovery

o   Biomedical Research

  • Viral Vector Production Market, By End User:

o   Pharmaceutical and Biopharmaceutical Companies

o   Research Institutes

  • Global Viral Vector Production Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector Production Market.

Available Customizations:

Global Dyes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Viral Vector Production Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.   Markets Covered

1.2.2.   Years Considered for Study

1.2.3.   Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Viral Vector Production Market Outlook

5.1.  Market Size & Forecast

5.1.1.   By Value

5.2.  Market Share & Forecast

5.2.1.   By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others)

5.2.2.   By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish)

5.2.3.   By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research)

5.2.4.   By End-Use Industry (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)

5.2.5.   By Company (2022)

5.2.6.   By Region

5.3.  Market Map

6.    North America Viral Vector Production Market Outlook

6.1.  Market Size & Forecast          

6.1.1.   By Value

6.2.  Market Share & Forecast

6.2.1.   By Vector Type

6.2.2.   By Workflow

6.2.3.   By Application

6.2.4.   By End User

6.2.5.   By Country

6.3.  North America: Country Analysis

6.3.1.   United States Viral Vector Production Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1.               By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1.             By Vector Type

6.3.1.2.2.             By Workflow

6.3.1.2.3.             By Application

6.3.1.2.4.             By End User

6.3.2.   Mexico Viral Vector Production Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1.               By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1.             By Vector Type

6.3.2.2.2.             By Workflow

6.3.2.2.3.             By Application

6.3.2.2.4.             By End User

6.3.3.   Canada Viral Vector Production Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1.               By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1.             By Vector Type

6.3.3.2.2.             By Workflow

6.3.3.2.3.             By Application

6.3.3.2.4.             By End User

7.    Europe Viral Vector Production Market Outlook

7.1.  Market Size & Forecast          

7.1.1.   By Value

7.2.  Market Share & Forecast

7.2.1.     By Vector Type

7.2.2.     By Workflow

7.2.3.     By Application

7.2.4.     By End User

7.2.5.   By Country

7.3.  Europe: Country Analysis

7.3.1.   France Viral Vector Production Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1.               By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1.             By Vector Type

7.3.1.2.2.             By Workflow

7.3.1.2.3.             By Application

7.3.1.2.4.             By End User

7.3.2.   Germany Viral Vector Production Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1.               By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1.             By Vector Type

7.3.2.2.2.             By Workflow

7.3.2.2.3.             By Application

7.3.2.2.4.             By End User

7.3.3.   United Kingdom Viral Vector Production Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1.               By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1.             By Vector Type

7.3.3.2.2.             By Workflow

7.3.3.2.3.             By Application

7.3.3.2.4.             By End User

7.3.4.   Italy Viral Vector Production Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1.               By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1.             By Vector Type

7.3.4.2.2.             By Workflow

7.3.4.2.3.             By Application

7.3.4.2.4.             By End User

7.3.5.   Spain Viral Vector Production Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1.               By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1.             By Vector Type

7.3.5.2.2.             By Workflow

7.3.5.2.3.             By Application

7.3.5.2.4.             By End User

8.    Asia-Pacific Dyes Market Outlook

8.1.  Market Si Viral Vector Production ze & Forecast         

8.1.1.   By Value

8.2.  Market Share & Forecast

8.2.1.     By Vector Type

8.2.2.     By Workflow

8.2.3.     By Application

8.2.4.     By End User

8.2.5.   By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.   China Viral Vector Production Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1.               By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1.             By Vector Type

8.3.1.2.2.             By Workflow

8.3.1.2.3.             By Application

8.3.1.2.4.             By End User

8.3.2.   India Viral Vector Production Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1.               By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1.             By Vector Type

8.3.2.2.2.             By Workflow

8.3.2.2.3.             By Application

8.3.2.2.4.             By End User

8.3.3.   South Korea Viral Vector Production Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1.               By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1.             By Vector Type

8.3.3.2.2.             By Workflow

8.3.3.2.3.             By Application

8.3.3.2.4.             By End User

8.3.4.   Japan Viral Vector Production Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1.               By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1.             By Vector Type

8.3.4.2.2.             By Workflow

8.3.4.2.3.             By Application

8.3.4.2.4.             By End User

8.3.5.   Australia Viral Vector Production Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1.               By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1.             By Vector Type

8.3.5.2.2.             By Workflow

8.3.5.2.3.             By Application

8.3.5.2.4.             By End User

9.    South America Viral Vector Production Market Outlook

9.1.  Market Size & Forecast          

9.1.1.   By Value

9.2.  Market Share & Forecast

9.2.1.     By Vector Type

9.2.2.     By Workflow

9.2.3.     By Application

9.2.4.     By End User

9.2.5.   By Country

9.3.  South America: Country Analysis

9.3.1.   Brazil Viral Vector Production Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1.               By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1.             By Vector Type

9.3.1.2.2.             By Workflow

9.3.1.2.3.             By Application

9.3.1.2.4.             By End User

9.3.2.   Argentina Viral Vector Production Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1.               By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1.             By Vector Type

9.3.2.2.2.             By Workflow

9.3.2.2.3.             By Application

9.3.2.2.4.             By End User

9.3.3.   Colombia Viral Vector Production Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1.               By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1.             By Vector Type

9.3.3.2.2.             By Workflow

9.3.3.2.3.             By Application

9.3.3.2.4.             By End User

10.  Middle East and Africa Viral Vector Production Market Outlook

10.1.              Market Size & Forecast

10.1.1.                By Value

10.2.              Market Share & Forecast

10.2.1.  By Vector Type

10.2.2.  By Workflow

10.2.3.  By Application

10.2.4.  By End User

10.2.5.                By Country

10.3.              MEA: Country Analysis

10.3.1.                South Africa Viral Vector Production Market Outlook

10.3.1.1.              Market Size & Forecast

10.3.1.1.1.             By Value

10.3.1.2.              Market Share & Forecast

10.3.1.2.1.           By Vector Type

10.3.1.2.2.           By Workflow

10.3.1.2.3.           By Application

10.3.1.2.4.           By End User

10.3.2.                Saudi Arabia Viral Vector Production Market Outlook

10.3.2.1.              Market Size & Forecast

10.3.2.1.1.             By Value

10.3.2.2.              Market Share & Forecast

10.3.2.2.1.           By Vector Type

10.3.2.2.2.           By Workflow

10.3.2.2.3.           By Application

10.3.2.2.4.           By End User

10.3.3.                UAE Viral Vector Production Market Outlook

10.3.3.1.              Market Size & Forecast

10.3.3.1.1.             By Value

10.3.3.2.              Market Share & Forecast

10.3.3.2.1.           By Vector Type

10.3.3.2.2.           By Workflow

10.3.3.2.3.           By Application

10.3.3.2.4.           By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  Competitive Landscape

15.1.              Business Overview

15.2.              Company Snapshot

15.3.              Products & Services

15.4.              Financials (In case of listed companies)

15.5.              Recent Developments

15.6.              SWOT Analysis

15.6.1.                Merck kgaa

15.6.2.                Lonza

15.6.3.                FUJIFILM Diosynth Biotechnologies U.S.A

15.6.4.                Cobra Biologics Ltd.

15.6.5.                Thermofisher Scientific Inc.

15.6.6.                Waisman Biomanufacturing

15.6.7.                Genezen Laboratories

15.6.8.                YPOSKESI

15.6.9.                Advanced BioScience Laboratories, Inc. (ABL inc.)

15.6.10.              Novasep Holding s.a.s.

15.6.11.              Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)

15.6.12.              Takara Bio Inc.

15.6.13.              RegenxBio, Inc.

15.6.14.              Aldevron LLc.

15.6.15.              Bluebird Bio Inc.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The pandemic led to disruptions in global supply chains, affecting the availability of raw materials and critical components used in viral vector production.

down-arrow

Merck kgaa, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A, Cobra Biologics Ltd., Thermofisher Scientific Inc., Waisman Biomanufacturing, Genezen Laboratories are some of the key players operating in the Global Viral Vector Production Market.

down-arrow

The public's understanding and acceptance of gene therapies, including those that utilize viral vectors, play a role in shaping the market's success. Addressing concerns, providing accurate information, and building trust are ongoing challenges for the industry.

down-arrow

The complexity of viral vector production has led to increased collaborations between academic institutions, biotechnology companies, and contract manufacturing organizations (CMOs).

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Viral Vector Production Market to grow with a CAGR of 14.21% through 2028

Nov, 2023

Rising Prevalence of Genetic Disorders and initiatives taken by the government are the major drivers for the Global Viral Vector Production Market.

Why Choose Us